Favourable release kinetics and a higher sensitivity than hs-cTn assays are likely responsible for the better performance in patients presenting early after chest pain onset.
Cardiac myosin-binding protein C (cMyC) is a promising novel biomarker of myocardial injury. Its discovery relied on the characterization of ‘impurities’ detected alongside myosin. cMyC has distinctive release kinetics that should enable it to act as a better adjudicator of acute versus chronic myocardial injury than troponin.
The cMyC test correctly excluded a heart attack in 32 per cent of patients.
It could mean thousands of patients are given the all-clear and sent home within quarter of an hour of arriving at A&E. Resulting in cost savings for healthcare.
Research related to heart attacks shows that the cMyC test has the potential to reassure many thousands more patients with a single test, freeing up valuable hospital beds in ED / A&E.